机构名称：
¥ 1.0
• Vividion Therapeutics (a wholly owned and independently operated subsidiary of Bayer AG) in its strategic collaboration with Tavros Therapeutics to discover and enhance targeted oncology programs, including an upfront of USD 17.5 million, up to USD 430.5 million in milestone payments for four initial programs, and, if Vividion exercises its opt- in for up to five more targets, up to USD 482额外付款。
代表性法律事务 - Oren Livne
主要关键词
相关文件推荐
